LTRN Lantern Pharma Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1763950 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY27.2%
TTM EPS YoY17.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-250.6%
ROA-124.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets83.5%
Debt / equity0.00x
Current ratio1.49x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-8.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $11.51M | $16.13M |
| SG&A expense | $6.46M | $6.09M |
| Operating income | -$17.98M | -$22.22M |
| Pretax income | $16.98M | — |
| Net income | -$17.12M | -$20.78M |
| EBITDA | -$17.96M | -$22.20M |
| EPS (basic) | -1.57 | -1.93 |
| EPS (diluted) | -1.57 | -1.93 |
| Weighted avg. shares (diluted) | 10.90M | 10.76M |
| Balance sheet | ||
| Cash & equivalents | $4.42M | $7.51M |
| Short-term investments | $5.70M | $16.50M |
| Current assets | $10.80M | $25.25M |
| PP&E, net | $31,875 | $47,440 |
| Total assets | $11.04M | $25.57M |
| Current liabilities | $4.50M | $4.33M |
| Total liabilities | $4.50M | $4.38M |
| Shareholders' equity | $6.53M | $21.19M |
| Shares outstanding | 11.25M | 10.78M |
| Cash flow statement | ||
| Operating cash flow | -$15.68M | -$17.81M |
| Capital expenditure | $1,715 | $12,595 |
| Free cash flow | -$15.68M | -$17.83M |
| Investing cash flow | $11.06M | $3.37M |
| Financing cash flow | $1.50M | $66,710 |
| Depreciation & amortization | $17,280 | $17,282 |
| Stock-based compensation | $651,000 | $652,000 |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.